BlackRock Advisors LLC reduced its position in shares of Intra-Cellular Therapies Inc. (NASDAQ:ITCI) by 0.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,257,910 shares of the biopharmaceutical company’s stock after selling 12,062 shares during the period. BlackRock Advisors LLC owned 2.91% of Intra-Cellular Therapies worth $48,832,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. increased its position in Intra-Cellular Therapies by 49.6% in the second quarter. Vanguard Group Inc. now owns 2,355,713 shares of the biopharmaceutical company’s stock worth $91,449,000 after buying an additional 781,550 shares in the last quarter. TimesSquare Capital Management LLC increased its position in Intra-Cellular Therapies by 15.6% in the first quarter. TimesSquare Capital Management LLC now owns 1,524,375 shares of the biopharmaceutical company’s stock worth $42,378,000 after buying an additional 205,955 shares in the last quarter. Renaissance Technologies LLC increased its position in Intra-Cellular Therapies by 423.3% in the first quarter. Renaissance Technologies LLC now owns 233,900 shares of the biopharmaceutical company’s stock worth $6,502,000 after buying an additional 189,200 shares in the last quarter. Columbus Circle Investors increased its position in Intra-Cellular Therapies by 39.9% in the second quarter. Columbus Circle Investors now owns 552,104 shares of the biopharmaceutical company’s stock worth $21,433,000 after buying an additional 157,498 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its position in Intra-Cellular Therapies by 209.7% in the second quarter. JPMorgan Chase & Co. now owns 146,276 shares of the biopharmaceutical company’s stock worth $5,678,000 after buying an additional 99,051 shares in the last quarter. Hedge funds and other institutional investors own 70.15% of the company’s stock.

Shares of Intra-Cellular Therapies Inc. (NASDAQ:ITCI) opened at 44.48 on Monday. The company has a 50-day moving average price of $41.35 and a 200 day moving average price of $36.40. Intra-Cellular Therapies Inc. has a 1-year low of $22.41 and a 1-year high of $60.79. The company’s market capitalization is $1.92 billion.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.08. The firm had revenue of $0.23 million for the quarter, compared to analyst estimates of $0.02 million. During the same period last year, the company posted ($0.61) earnings per share. The firm’s quarterly revenue was up 283.3% compared to the same quarter last year. Equities research analysts anticipate that Intra-Cellular Therapies Inc. will post ($3.17) EPS for the current year.

A number of research analysts have weighed in on ITCI shares. Cowen and Company restated a “buy” rating and issued a $75.00 price target on shares of Intra-Cellular Therapies in a research note on Friday, August 5th. Piper Jaffray Cos. reiterated an “overweight” rating and set a $57.00 target price on shares of Intra-Cellular Therapies in a research note on Tuesday, September 13th. Leerink Swann reiterated a “buy” rating on shares of Intra-Cellular Therapies in a research note on Thursday, June 30th. Finally, Zacks Investment Research upgraded Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $42.00 target price for the company in a research note on Wednesday, June 29th. One analyst has rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $70.25.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

5 Day Chart for NASDAQ:ITCI

Receive News & Ratings for Intra-Cellular Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.